Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Sep 14;12(9):e0184113.
doi: 10.1371/journal.pone.0184113. eCollection 2017.

Characterization of a novel panel of plasma microRNAs that discriminates between Mycobacterium tuberculosis infection and healthy individuals

Jia-Yi Cui  1   2   3 , Hong-Wei Liang  4 , Xin-Ling Pan  1   2   3 , Di Li  1   2   3 , Na Jiao  5 , Yan-Hong Liu  6 , Jin Fu  7 , Xiao-Yu He  1   2   3 , Gao-Xiang Sun  1   2   3 , Chun-Lei Zhang  5 , Chi-Hao Zhao  4 , Dong-Hai Li  4 , En-Yu Dai  1   2   3 , Ke Zen  4 , Feng-Min Zhang  1   2   3 , Chen-Yu Zhang  3   4 , Xi Chen  4 , Hong Ling  1   2   3   8
Affiliations
Clinical Trial

Characterization of a novel panel of plasma microRNAs that discriminates between Mycobacterium tuberculosis infection and healthy individuals

Jia-Yi Cui et al. PLoS One. .

Abstract

Cavities are important in clinical diagnosis of pulmonary tuberculosis (TB) infected by Mycobacterium tuberculosis. Although microRNAs (miRNAs) play a vital role in the regulation of inflammation, the relation between plasma miRNA and pulmonary tuberculosis with cavity remains unknown. In this study, plasma samples were derived from 89 cavitary pulmonary tuberculosis (CP-TB) patients, 89 non-cavitary pulmonary tuberculosis (NCP-TB) patients and 95 healthy controls. Groups were matched for age and gender. In the screening phase, Illumina high-throughput sequencing technology was employed to analyze miRNA profiles in plasma samples pooled from CP-TB patients, NCP-TB patients and healthy controls. During the training and verification phases, quantitative RT-PCR (qRT-PCR) was conducted to verify the differential expression of selected miRNAs among groups. Illumina high-throughput sequencing identified 29 differentially expressed plasma miRNAs in TB patients when compared to healthy controls. Furthermore, qRT-PCR analysis validated miR-769-5p, miR-320a and miR-22-3p as miRNAs that were differently present between TB patients and healthy controls. ROC curve analysis revealed that the potential of these 3 miRNAs to distinguish TB patients from healthy controls was high, with the area under the ROC curve (AUC) ranged from 0.692 to 0.970. Moreover, miR-320a levels were decreased in drug-resistant TB patients than pan-susceptible TB patients (AUC = 0.882). In conclusion, we identified miR-769-5p, miR-320a and miR-22-3p as potential blood-based biomarkers for TB. In addition, miR-320a may represent a biomarker for drug-resistant TB.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart of the experimental design.
Fig 2
Fig 2. MiRNA expression in plasma derived from CP-TB, NCP-TB patients and healthy controls (H).
Fig 3
Fig 3. Detection of TB using 3 plasma miRNAs as a biomarker.
A hydrolysis probe–based qRT-PCR assay was used to measure the relative levels of the 3 miRNAs in 64 CP-TB patients, 64 NCP-TB patients and 64 healthy controls (in both the training and validation set). Each point represents the mean of the results for triplicate. The asterisks indicate significant differences compared to healthy controls. * P<0.05; ** P<0.01; *** P<0.001. (A) miR-769-5p, (B) miR-320a and (C) miR-22-3p.
Fig 4
Fig 4. ROC curves to compare the ability of miRNA to distinguish TB patients from the healthy controls.
(A-D) miR-769-5p, miR-320a, miR-22-3p and the three-miRNA panel for discriminating between NCP-TB patients and healthy controls; (E-H) miR-769-5p, miR-320a, miR-22-3p and the three-miRNA panel for discriminating between CP-TB patients and healthy controls; (I-L) miR-769-5p, miR-320a, miR-22-3p and the three-miRNA panel for discriminating between TB patients and healthy controls.
Fig 5
Fig 5. Downregulation of miR-320a in plasma from drug-resistant TB patients compared with drug-susceptible TB patients.
(A) Relative concentration of miR-320a in plasma derived from drug-resistant and drug-susceptible TB patients. (B) ROC curves to comparing the ability of miR-320a to distinguish between drug-resistant TB and drug-susceptible TB.
See this image and copyright information in PMC

References

    1. WHO. Global tuberculosis report World Organization Health; 2016. Available from: http://www.who.int/tb/publications/global_report/en/.
    1. Dorhoi A, Kaufmann SH. Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis. Seminars in immunopathology. 2016; 38 (2): 153–66. doi: 10.1007/s00281-015-0531-3 . - DOI - PubMed
    1. Barry S, Breen R, Lipman M, Johnson M, Janossy G. Impaired antigen-specific CD4(+) T lymphocyte responses in cavitary tuberculosis. Tuberculosis. 2009; 89 (1): 48–53. doi: 10.1016/j.tube.2008.07.002 . - DOI - PubMed
    1. Welsh KJ, Risin SA, Actor JK, Hunter RL. Immunopathology of postprimary tuberculosis: increased T-regulatory cells and DEC-205-positive foamy macrophages in cavitary lesions. Clinical & developmental immunology. 2011; 307631. doi: 10.1155/2011/307631 . - DOI - PMC - PubMed
    1. Ko JM, Park HJ, Kim CH, Song SW. The relation between CT findings and sputum microbiology studies in active pulmonary tuberculosis. European journal of radiology. 2015; 84 (11): 2339–44. doi: 10.1016/j.ejrad.2015.07.032 . - DOI - PubMed

Publication types

LinkOut - more resources